SCHEMBL17192085

SCHEMBL17192085

CC(C)c1c(O)c(O)cc[n+]1C(C)C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RNASEH1 O60930 1/20 0.33
GABRA1 P14867 2/20 0.32
GABRB2 P47870 2/20 0.32
FAAH O00519 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
LMNA P02545 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
GABRB1 P18505 1/20 0.32
GABRG2 P18507 1/20 0.32
PTGS1 P23219 1/20 0.32
SLC6A2 P23975 1/20 0.32
HTR2C P28335 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
GABRA3 P34903 1/20 0.32
HTR2B P41595 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17192059 0.80 CDC42 (0.36) RNASEH1HIF1A
SCHEMBL17192069 0.78 CDK2 (0.35) RNASEH1
SCHEMBL17192067 0.72 CDC42 (0.33)
SCHEMBL19420607 0.67 GABRA1 (0.34) RNASEH1GABRA1GABRB2FAAHCA1
SCHEMBL19420582 0.67 GABRA1 (0.34) RNASEH1GABRA1GABRB2FAAHCA1
SCHEMBL17192080 0.67 GABRA1 (0.46) GABRA1GABRB2FAAHCA1CA2
SCHEMBL19677605 0.64 SLC22A3 (0.41) GABRA1GABRB2LMNACYP1A2
SCHEMBL15631181 0.64 ALDH1A1 (0.36) CYP3A4HPGDTSHRHIF1A
SCHEMBL19426153 0.62 PTPN22 (0.38) RNASEH1LMNABLM
SCHEMBL19426154 0.62 BAD (0.39) RNASEH1LMNAHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10174053-B2 2 substituted cephem compounds GLAXO GROUP LIMITED (GB) 2019-01-08 US disclosed
US-20170281532-A1 2 SUBSTITUTED CEPHEM COMPOUNDS GLAXO GROUP LIMITED (GB) 2017-10-05 US disclosed
US-20170281532-A1 2 SUBSTITUTED CEPHEM COMPOUNDS GLAXO GROUP LIMITED (GB) 2017-10-05 US disclosed
US-20150299223-A1 2-SUBSTITUTED CEPHEM COMPOUNDS GLAXO GROUP LTD (GB) 2015-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281532-A1 2 SUBSTITUTED CEPHEM COMPOUNDS CEP170, CES2, CMBL RNASEH1 3539/4885GABRA1 3836/4885GABRB2 2708/4885
US-20150299223-A1 2-SUBSTITUTED CEPHEM COMPOUNDS CEP170, ABL1, CEPT1 RNASEH1 3773/4885GABRA1 3713/4885GABRB2 2610/4885
US-10174053-B2 2 substituted cephem compounds CEP170, CES2, CMBL RNASEH1 3539/4885GABRA1 3836/4885GABRB2 2708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.